Academic society to retract push for eugenic protection law 66 yrs after its proposal
By Norikazu Chiba,
The Mainichi
| 12. 19. 2018
TOKYO -- The Japanese Society for Hygiene, which was active in promoting eugenic policies under the now-defunct eugenic protection law, has decided to retract its proposal made 66 years ago to the government for the use of forced sterilization operations as a means of population control, judging that the move was discriminatory.
It will be the first official admission of a mistake by an academic society among several, such as those for psychiatric medicine or social sciences, which supported sterilization operations against people with mental or physical disabilities that were deemed very serious or hereditary. As many as 25,000 people are believed to have received such surgeries under the 1948-1996 law that is now deemed inhuman, and multiple political parties are putting together a plan to compensate those victims.
Chairman Takemi Otsuki of the society, who also serves as professor of hygiene at Kawasaki Medical School, explains that the society reached the decision as measures have been taken to support the victims of forced sterilization operations. "We want to play a new role to stem the decline in the number...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...